We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure (IPGE1)

This study has been withdrawn prior to enrollment.
(Withdrawn due to lack of recruitment)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00598429
First Posted: January 21, 2008
Last Update Posted: December 9, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by (Responsible Party):
NICHD Neonatal Research Network
January 10, 2008
January 21, 2008
December 9, 2016
May 2008
September 2008   (Final data collection date for primary outcome measure)
The ability to recruit an adequate number of patients (n = 50) in a 6-9 month period without excessive (>20%) protocol violations. [ Time Frame: 6-9 months after trial begins recruitment ]
Same as current
Complete list of historical versions of study NCT00598429 on ClinicalTrials.gov Archive Site
  • Progression to an OI greater than 25 [ Time Frame: 72-hours after enrollment ]
  • Improvement in partial pressure of oxygen (PaO2) in the blood gas [ Time Frame: 72-hours after enrollment ]
  • Change in OI [ Time Frame: 72 hours after enrollment ]
  • Death [ Time Frame: 72-hours after intervention ]
  • Need for inhaled nitric oxide or ECMO [ Time Frame: 72-hours after enrollment ]
  • Length of hospitalization
  • Duration of mechanical ventilation
  • Number of days of oxygen used and need for supplemental oxygen at 28 days of life
  • Occurrence of grade III-IV intracranial hemorrhage and cystic leukomalacia
Same as current
Not Provided
Not Provided
 
Inhaled PGE1 in Neonatal Hypoxemic Respiratory Failure
Randomized Clinical Trial of Inhaled PGE1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure. A Protocol for the NICHD Neonatal Research Network
This pilot study was a randomized, placebo-controlled, clinical trial to test the safety of using the intravenous form of Prostaglandin E1 (PGE1) in an inhaled form for treatment of hypoxemic respiratory failure in term newborns. The study planned to enroll 50 infants diagnosed with hypoxemic respiratory failure at nine NICHD Neonatal Research Network sites, and randomly assign them to receive one dose over a 72-hour period of either high concentration PGE1 (300 ng/kg/min), low concentration PGE1 (150 ng/kg/min), or placebo (normal saline, the diluent for the drug). In addition to determining the safety, optimal dose, and duration of the therapy, this pilot trial planned to evaluate the feasibility of conducting a larger, multi-center randomized, blinded placebo-controlled trial.

Hypoxemic respiratory failure (HRF), frequently associated with persistent pulmonary hypertension of the newborn (PPHN), is a rare, but life-threatening condition affecting approximately 2 to 9 percent of infants admitted to neonatal intensive care units and results in significant morbidity and mortality. It occurs more often in full- or post-term babies whose circulatory systems do not adapt well to breathing outside the womb. HRF may result from congenital hernia of the diaphragm, group B streptococcal infection, inhaling meconium in the womb, or respiratory distress syndrome.

Medical treatments, such as high frequency ventilation, inhaled nitric oxide, and Extracorporeal Membrane Oxygenation (ECMO, a heart and lung support machine), have significantly increased survival of children with HRF. These therapies, while successful, however, have a variety of side effects and potential long-term disabilities.

This feasibility trial was designed to test the safety of using the intravenous form of Prostaglandin E1 in an inhaled form (iPGE1) on infants born at 34 0/7ths weeks gestational age or greater diagnosed with hypoxemic respiratory failure and on assisted ventilation. The intravenous form of PGE1 was to be aerosolized and administered via a nebulizer attached to the infant's ventilator. The goal was to enroll 50 subjects within 6-9 months, in preparation for a larger, multi-center randomized control trial; however, the study was withdrawn for lack of recruitment.

Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Infant, Newborn
  • Respiratory Insufficiency
  • Pulmonary Hypertension
  • Respiratory Distress Syndrome, Newborn
  • Streptococcal Infections
Drug: Inhaled Prostaglandin E1
Delivery of one dose of either high dose PGE1 (300 ng/kg/min), low dose PGE1 (150 ng/kg/min), or placebo (normal saline, the diluent for the drug) via nebulizer over a 72-hour period
Other Name: Alprostadil
  • Active Comparator: High dose
    PGE1 300 ng/kg/min via nebulizer over a 72-hour period
    Intervention: Drug: Inhaled Prostaglandin E1
  • Active Comparator: Low dose
    PGE1 150 ng/kg/min via nebulizer over a 72-hour period
    Intervention: Drug: Inhaled Prostaglandin E1
  • Placebo Comparator: Placebo
    Normal saline, the diluent for the drug, via nebulizer over a 72-hour period
    Intervention: Drug: Inhaled Prostaglandin E1
Sood BG, Keszler M, Garg M, Klein JM, Ohls R, Ambalavanan N, Cotten CM, Malian M, Sanchez PJ, Lakshminrusimha S, Nelin LD, Van Meurs KP, Bara R, Saha S, Das A, Wallace D, Higgins RD, Shankaran S; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Inhaled PGE1 in neonates with hypoxemic respiratory failure: two pilot feasibility randomized clinical trials. Trials. 2014 Dec 12;15:486. doi: 10.1186/1745-6215-15-486.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
September 2008
September 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Infants born at 34 0/7ths weeks gestational age or greater (by best obstetrical estimate) and at a postnatal age no greater than 7 days (168 hours)
  • Infants diagnosed with hypoxemic respiratory failure (HRF), including perinatal aspiration syndrome (meconium, blood, or amniotic fluid), pneumonia/ sepsis, respiratory distress syndrome, or idiopathic respiratory failure
  • Infants who will receive assisted ventilation for HRF
  • Infants with an oxygenation index (MAP x FiO2 x 100/PaO2)(OI) of 15-25 on two arterial gases taken between 15 minutes and 12 hours apart
  • An indwelling arterial line
  • Infants whose parents/legal guardians have provided consent for enrollment

Exclusion Criteria:

  • Any infant in whom a decision has been made not to provide full treatment
  • Known structural congenital heart disease, except patent ductus arteriosus and atrial/ventricular level shunts
  • Congenital diaphragmatic hernia
  • Preterm neonates less than 34 weeks
  • Thrombocytopenia (platelet count < 80,000/μl) unresponsive to platelet transfusion
  • Infants receiving hypothermia for hypoxic ischemic encephalopathy
  • Previous treatment with inhaled nitric oxide
  • Infants already enrolled in a conflicting and/or Investigational New Drug (IND) clinical trial
  • Infants whose parents/legal guardians refuse consent
Sexes Eligible for Study: All
up to 7 Days   (Child)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00598429
NICHD-NRN-0037
U10HD036790 ( U.S. NIH Grant/Contract )
U10HD021364 ( U.S. NIH Grant/Contract )
U10HD021385 ( U.S. NIH Grant/Contract )
U10HD027880 ( U.S. NIH Grant/Contract )
U10HD034216 ( U.S. NIH Grant/Contract )
U10HD040492 ( U.S. NIH Grant/Contract )
U10HD040689 ( U.S. NIH Grant/Contract )
U10HD053089 ( U.S. NIH Grant/Contract )
U10HD053109 ( U.S. NIH Grant/Contract )
U10HD053119 ( U.S. NIH Grant/Contract )
U10HD053124 ( U.S. NIH Grant/Contract )
Yes
Not Provided
Not Provided
NICHD Neonatal Research Network
NICHD Neonatal Research Network
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Principal Investigator: Michele C. Walsh, MD MS Case Western Reserve University, Rainbow Babies and Children's Hospital
Principal Investigator: Ronald N. Goldberg, MD Duke University
Principal Investigator: Krisa P. Van Meurs, MD Stanford University
Principal Investigator: Ivan D. Frantz III, MD Tufts Medical Center
Principal Investigator: Waldemar A. Carlo, MD University of Alabama at Birmingham
Principal Investigator: Edward F. Bell, MD University of Iowa
Principal Investigator: Kristi L. Watterberg, MD University of New Mexico
Principal Investigator: Roger G. Faix, MD University of Utah
Principal Investigator: Seetha Shankaran, MD Wayne State University
Principal Investigator: Pablo J. Sanchez, MD University of Texas, Southwestern Medical Center at Dallas
NICHD Neonatal Research Network
July 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP